Monday, November 4, 2019

Bellicum up 26% ahead of data presentation on CAR program

Nano cap Bellicum Pharmaceuticals (BLCM +26.2%) jumps on a 2.5x surge in volume, adding to its 30% move on Friday.
No particular news accounts for the action, but this Friday, November 8, an abstract on its natural killer cell chimeric antigen receptor (CAR) program will be presented at the SITC Annual Meeting in Maryland.
The company’s technology, GoCAR-T, is the basis for pipeline candidates BPX-601 and BPX-603.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.